organization · Reporting owner
Cystic Fibrosis Foundation
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aridis Pharmaceuticals, Inc.ARDS · Entity 89417 | 10% owner | December 08, 2022 | December 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aridis Pharmaceuticals, Inc.
Report date December 08, 2022 · Filed December 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 5,168,732 |
Reported balance
Holding disclosure · report date 2022-12-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,168,732 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tessera Defense & Homeland Security Inc.
Report date February 26, 2025 · Filed March 04, 2025
Section 16 reporting ended · disclosed 2025-03-04. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2024 Filed Mar 4, 2025 21:31 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | ConversionSeries X Preferred Stock · Derivative | 8,547 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032174 · ownership.xml · derivative · entry 2 Cystic Fibrosis Foundation · CIK 0001957515 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,088 Underlying: Common Stock · 854,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: In accordance with the Certificate of Designation of Preferences, Rights and Limitations (the "Certificate of Designation") governing the Series X Non-Voting Convertible Preferred Stock ("Series X Preferred Stock"), on July 15, 2024 (the "Stockholder Approval Date"), 8,547 shares of Series X Preferred Stock held by the Reporting Person automatically converted into 8,547,000 shares of Common Stock; following the Reverse Split, such shares were combined to 854,700 shares of Common Stock. F3 · derivative.exercise_date: As of the third business day after the Stockholder Approval Date, each share of Series X Preferred Stock became convertible at any time at the election of the holder into 100 shares of Common Stock (as adjusted pursuant to the Reverse Split, and subject to further adjustment), subject to a beneficial ownership limitation, in accordance with the Certificate of Designation. The Series X Preferred Stock has no expiration date. F3 · derivative.expiration_date: As of the third business day after the Stockholder Approval Date, each share of Series X Preferred Stock became convertible at any time at the election of the holder into 100 shares of Common Stock (as adjusted pursuant to the Reverse Split, and subject to further adjustment), subject to a beneficial ownership limitation, in accordance with the Certificate of Designation. The Series X Preferred Stock has no expiration date. F1 · derivative.underlying_shares: Reflects a ten-for-one reverse stock split of the Issuer's common stock that was effected on August 26, 2024 (the "Reverse Split"). Read SEC document |
| July 15, 2024 Filed Mar 4, 2025 21:31 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | ConversionCommon Stock, par value $0.0001 per share | 854,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-032174 · ownership.xml · nonDerivative · entry 1 Cystic Fibrosis Foundation · CIK 0001957515 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,787,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a ten-for-one reverse stock split of the Issuer's common stock that was effected on August 26, 2024 (the "Reverse Split"). F2 · price: In accordance with the Certificate of Designation of Preferences, Rights and Limitations (the "Certificate of Designation") governing the Series X Non-Voting Convertible Preferred Stock ("Series X Preferred Stock"), on July 15, 2024 (the "Stockholder Approval Date"), 8,547 shares of Series X Preferred Stock held by the Reporting Person automatically converted into 8,547,000 shares of Common Stock; following the Reverse Split, such shares were combined to 854,700 shares of Common Stock. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:05 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | OtherWarrant to purchase common stock · Derivative | 4,778,265 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061622 · ownership.xml · derivative · entry 2 Cystic Fibrosis Foundation · CIK 0001957515 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,778,265 shares Expires not disclosed F1 · derivative.exercise_date: The warrant was exercisable beginning on February 27, 2023, for that number of shares that would not result in the Reporting Person beneficially owning more than 9.99% of the number of shares of common stock then issued and outstanding upon such exercise, and became exercisable in full on May 15, 2024. The warrant does not expire. F1 · derivative.expiration_date: The warrant was exercisable beginning on February 27, 2023, for that number of shares that would not result in the Reporting Person beneficially owning more than 9.99% of the number of shares of common stock then issued and outstanding upon such exercise, and became exercisable in full on May 15, 2024. The warrant does not expire. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:05 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | OtherCommon Stock, par value $0.0001 per share | 4,778,265 | $0.00 | $4,778.27 |
DisclosureSEC source: 0000950170-24-061622 · ownership.xml · nonDerivative · entry 1 Cystic Fibrosis Foundation · CIK 0001957515 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,330,580 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.